ACP
MREO

Acuta Capital Partners’s Mereo BioPharma MREO Stock Holding History

Acuta Capital Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-791,815
Closed -$1.78M – 33
2025
Q1 		$1.78M Buy
791,815
+12,507
+2% +$35.4K 2.07% 20
2024
Q4 		$2.73M Sell
779,308
-481,392
-38% -$1.89M 2.74% 13
2024
Q3 		$5.18M Buy
1,260,700
+583,700
+86% +$2.41M 4.2% 8
2024
Q2 		$2.44M Buy
677,000
+279,116
+70% +$904K 2.05% 20
2024
Q1 		$1.31M Buy
+397,884
New +$1.35M 0.85% 27

Other funds holding MREO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acuta Capital Partners's MREO Position: Q2 2025 in Review

Acuta Capital Partners sold out of Mereo BioPharma (MREO) in Q2 2025, closing a stake of 791,815 shares — an estimated $1.78M sold.

Acuta Capital Partners first reported a position in MREO in Q1 2024 and held it in 5 quarters. The position peaked at $5.18M in Q3 2024. 86 funds tracked by Wall St. Rank hold MREO as of Q2 2025.

  • Acuta Capital Partners reported no remaining Mereo BioPharma position as of Q2 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 791,815 Mereo BioPharma shares in Q2 2025, an estimated $1.78M.
  • Acuta Capital Partners first reported a position in Mereo BioPharma in Q1 2024 and held it in 5 quarters.
  • Acuta Capital Partners's Mereo BioPharma position peaked at $5.18M in Q3 2024.
  • 86 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2025.

Based on Acuta Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.